Plasma Fractionation Market Size, Share and Forecast (2019-2026)

SKU: DHC272 | Last Updated On: 2019-08-19 | No. of Pages: 210 | Available Formats

( 46 Samples have been requested. )
In June 2019, Grifols launched the VISTASEAL™ fibrin sealant with Ethicon Inc. as part of a global relationship to provide plasma-protein-based solutions to manage surgical bleeding.

Plasma Fractionation Market

Plasma fractionation is a method of separating various components of blood plasma to treat protein deficiency in individuals and also in industrial applications as packaging material. It is used in the prevention and treatment of life-threatening diseases caused by trauma, immunologic disorders, and infections. The global Plasma Fractionation market size was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period (2019-2026).

Global Plasma Fractionation Market Value (USD Mn), 2018-2026

Plasma Fractionation Market Dynamics

The rising prevalence of respiratory diseases and alpha-1 antitrypsin deficiency (ATTD) along with growing geriatric population, increasing use of immunoglobulins in various therapeutic applications are some of the factors driving the growth of the plasma fractionation market. 
Alpha-1 Antitrypsin (AAT) is a protein made in the liver in healthy humans, and certain genetic defects diminish or eliminate the liver’s ability to make AAT. An AAT deficiency causes a variety of conditions, including emphysema, neonatal hepatitis, jaundice, and chronic obstructive pulmonary disease (COPD). Alpha1-antitrypsin deficiency (AATD) is one of the most common genetic disorders associated with significant morbidity and mortality. The prevalence of diagnosed AATD increases with age. According to the European Respiratory Journal, 2017, it is estimated that the number of diagnosed AATD patients in Germany was 19 162, of whom an estimated 8684 patients would have had an additional pulmonary diagnosis. The prevalence of COPD and emphysema in AATD was 32% and 21%, respectively. In addition, according to the WHO, Respiratory diseases are leading causes of death and disability in the world. About 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. About 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children globally. Hence, the rising prevalence of various respiratory diseases and Alpha1-antitrypsin deficiency (AATD) is driving the growth of the plasma fractionation market globally.
Various advancements in the product by major manufacturers is also one of the major factor contributing to the growth of the market. For instance, in June 2019, Grifols, launched the VISTASEAL™ fibrin sealant with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Also, in September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.

However, the high cost of plasma products, the emergence of recombinant alternatives, and limited reimbursements are some of the factors hindering the growth of the plasma fractionation market during the forecast period.

Plasma Fractionation Market Segment Analysis

By product, the plasma fractionation market is segmented into albumin, immunoglobulins, coagulation factor concentrates, protease inhibitors, and others. Among these, the immunoglobulin segment accounted for the largest market share in 2018 and expected to dominate the plasma fractionation market during the forecast period (2019-2026). The immunoglobulins segment is further classified into subcutaneous immunoglobulins, intravenous immunoglobulins, and others. The intravenous immunoglobulins (IVIg) held the largest market share in 2018 as it is the most extensively used plasma product globally for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, dermatomyositis, hypogammaglobinemia, Guillain-Barre syndrome, immune cytopenias, primary antibody deficiency, vacuities, asthma, and systemic lupus erythematosus, among other disorders. The rising prevalence of these disorders is fuelling the growth of this segment. The subcutaneous immunoglobulins (SCIg) segment is estimated to grow at the highest CAGR during the forecast period (2019-2026). SCIg has several advantages over IVIg such as; it is the best alternative for patients with limited vascular access who cannot tolerate adverse effects associated with IVIg. Slow administration and absorption of SCIg reduce the rapid variation in serum Ig levels, which further reduces adverse drug reactions. These advantages are expected to drive the growth in this product segment. The major players are innovating new products which lead to the growth of the immunoglobulins market. For instance, in September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.
The coagulation factor market is segmented into Von Willebrand Factor, Factor IX, Factor VIII, Factor XIII, Fibrinogen Concentrates, and Prothrombin Complex. Among these, the concentrate Factor VIII segment held the highest share in the coagulation factor concentrates market, owing to the rising geriatric population, rising number of hemophilic patients, increasing preference for prophylactic treatments for people suffering from hemophilia, and increasing diagnosis of hemophilia. In addition, the unavailability of advanced therapies in developing countries for a majority of hemophilia patients is also expected to drive the growth of this segment.

Global Plasma Fractionation Market Share (%), By Product, 2018

Plasma Fractionation Market Geographical Analysis

North America holds the dominant market share for plasma fractionation in 2018, and it is expected to maintain the growth over the forecast period, owing to increasing use of immunoglobulins in various applications such as neurological and autoimmune diseases. The growing number of respiratory diseases will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America. The burden of respiratory diseases is increasing in United States. According to the National Center for Health Statistics, currently more than 25 million people in the United States have asthma and approximately 14.8 million adults have been diagnosed with COPD. COPD is the 4th leading cause of death in the United States. According to the Centers for Disease Control and Prevention (CDC), in 2014, approximately 142,000 individuals died from COPD, and almost as many died from lung cancer (approximately 155,500) in the same year. In nearly 8 out of 10 cases, COPD is caused by exposure to cigarette smoke. Other environmental exposures (such as those in the workplace) may also cause COPD.
There are advancements in processes, improved formulations, and increased production efficiency. Advancement in technology leads to improved process of plasma manufacturing, hence leading to growth of the market in this region. There are many clinics across the region for targeted gene therapies with new advancements in treatments related to cardiovascular diseases, cancer immunotherapies, and blood-related disorders. Several innovations in manufacturing processes (e.g. improvement of yield), product developments (e.g. such as subcutaneous IG, IVIg 10% concentration, and IVIg liquid presentation), presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA are also supporting the growth of the plasma fractionation market in these regions. For instance, in August 2016, Shire, announced the U.S. launch of VONVENDI [von Willebrand factor (Recombinant)], the only recombinant treatment for adults living with von Willebrand disease (VWD). The treatment is also the first in the United States that has the option to dose recombinant von Willebrand factor (rVWF) independent of recombinant Factor VIII (rFVIII), based on patient need. This attribute allows for tailored treatment for patients who may not require additional FVIII.

Global Plasma Fractionation Market Share (%), By Geography, 2018

Plasma Fractionation Market Competitive Landscape

The Plasma Fractionation market is dominated by few major players including CSL, Grifols, China Biologic Products, Shire (Takeda Pharmaceutical Company), Octapharma Plasma, Inc., Kedrion S.p.A, Sanquin, and LFB SA. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the Plasma Fractionation market globally. For instance, 
In June 2019, Grifols, one of the world’s three top providers of plasma-derived medicines to treat life-threatening diseases, launched the VISTASEAL™ fibrin sealant with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. 
In March 2019, Grifols acquired $1.9 billion stake in Shanghai RAAS Blood Products Co., gaining a major foothold in China’s booming blood-products market.
In January 2019, Takeda Pharmaceutical Company Limited (Japan), a global biopharmaceutical company acquired Shire, increasing its geographic footprint and global customer base.
In September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.
In September 2018, Octapharma invested USD 25 million (Euro 21 million) in a new multi-function facility in Springe, Germany, that will have a new production line for human normal immunoglobulin panzyga, alongside with human albumi and albunorm.
In August 2018, Grifols acquired Biotest US Corporation, a subsidiary of Biotest (Germany), to expand its plasma collection network with the addition of 24 Biotest centers in the US.
In February 2018, Guizhou Taibang Biological Products Co. Ltd., a wholly-owned subsidiary of China Biologic Products Organization, received approval from the Hainan Provincial Health and Family Planning Commission to build a new plasma collection station in Hainan Province.

Why Purchase the Report?

  • Visualize the composition of the plasma fractionation products in various applications highlighting the key commercial assets and players.
  • Identify commercial opportunities in plasma fractionation market by analyzing trends and co-development deals. 
  • Excel data sheet with thousands of data points of plasma fractionation market-level 4/5 segmentation.
  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Plasma Fractionation Market

  1. Global Plasma Fractionation Market Methodology and Scope

    1. Research Methodology

    2. Research Objective and Scope of the Report

  2. Global Plasma Fractionation Market – Market Definition and Overview

  3. Global Plasma Fractionation Market – Executive Summary

    1. Market Snippet by Product

    2. Market Snippet by Application

    3. Market Snippet by End-User

  4. Global Plasma Fractionation Market Dynamics

    1. Market Impacting Factors

      1. Drivers

        1. Rising Prevalence of Respiratory Diseases

        2. Growing aging population globally

        3. Increasing demand of Immunoglobulins in various Therapeutic Areas

      2. Restraints

        1. Stringent Government Regulations

        2. High Cost and Limited Reimbursement

      3. Opportunity

      4. Impact Analysis

  5. Global Plasma Fractionation Market – Industry Analysis

    1. Porter's Five Forces Analysis

    2. Regulatory Analysis

    3. Supply Chain Analysis

    4. Pricing Analysis

    5. Unmet Needs

  6. Global Plasma Fractionation Market – By Product

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment

      2. Market Attractiveness Index, By Product Segment

    2. Albumin*

      1. Introduction

      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026

    3. Immunoglobulins

      1. Subcutaneous Immunoglobulins

      2. Intravenous Immunoglobulins

      3. Others

    4. Coagulation Factor Concentrates

      1. Von Willebrand Factor

      2. Factor IX

      3. Factor VIII

      4. Factor XIII

      5. Fibrinogen Concentrates

      6. Prothrombin Complex Concentrate

    5. Protease Inhibitors

    6. Others

  7. Global Plasma Fractionation Market – By Application

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment

      2. Market Attractiveness Index, By Application Segment

    2. Immunology*

      1. Introduction

      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026

    3. Neurology

    4. Hemato-Oncology 

    5. Hematology 

    6. Critical Care 

    7. Pulmonology

    8. Rheumatology

    9. Others

  8. Global Plasma Fractionation Market – By End-User

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment

      2. Market Attractiveness Index, By End-User Segment

    2. Clinical Research Laboratories*

      1. Introduction

      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026

    3. Hospitals & Clinics

    4. Academic Institutes

    5. Others

  9. Global Plasma Fractionation Market – By Region

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

      2. Market Attractiveness Index, By Region

    2. North America

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. U.S.

        2. Canada

        3. Mexico

    3. Europe

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. Germany

        2. U.K.

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

    4. South America

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. Brazil

        2. Argentina

        3. Rest of South America

    5. Asia Pacific

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. China

        2. India

        3. Japan

        4. Australia

        5. Rest of Asia Pacific

    6. Middle East and Africa

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

  10. Global Plasma Fractionation Market – Competitive Landscape

    1. Competitive Scenario

    2. Market Positioning/Share Analysis

    3. Mergers and Acquisitions Analysis

  11. Company Profiles

    1. CSL*

      1. Company Overview

      2. Product Portfolio and Description

      3. Key Highlights

      4. Financial Overview

    2. Grifols

    3. China Biologic Products 

    4. Shire (Takeda Pharmaceutical Company)

    5. Octapharma Plasma, Inc.

    6. Kedrion S.p.A

    7. Sanquin 

    8. LFB SA

  12. Global Plasma Fractionation Market – Premium Insights

  13. Global Plasma Fractionation Market – DataM

    1. Appendix

    2. About Us and Services

    3. Contact Us

List of Tables
Table 1    Global Plasma Fractionation Market Value, By Product, 2018, 2022 & 2026 ($ Million)
Table 2    Global Plasma Fractionation Market Value, By Application, 2018, 2022 & 2026 ($ Million)
Table 3    Global Plasma Fractionation Market Value, By End-User, 2018, 2022 & 2026 ($ Million)
Table 4    Global Plasma Fractionation Market Value, By Region, 2018, 2022 & 2026 ($ Million)
Table 5    Global Plasma Fractionation Market Value, By Product, 2018, 2022 & 2026 ($ Million)
Table 6    Global Plasma Fractionation Market Value, By Product, 2017-2026 ($ Million)
Table 7    Global Plasma Fractionation Market Value, By Application, 2018, 2022 & 2026 ($ Million)
Table 8    Global Plasma Fractionation Market Value, By Application, 2017-2026 ($ Million)
Table 9    Global Plasma Fractionation Market Value, By End-User, 2018,2022 & 2026 ($ Million)
Table 10    Global Plasma Fractionation Market Value, By End-User, 2017-2026 ($ Million)
Table 11    Global Plasma Fractionation Market Value, By Region, 2018,2022 & 2026 ($ Million)
Table 12    Global Plasma Fractionation Market Value, By Region, 2017-2026 ($ Million)
Table 13    North America Plasma Fractionation Market Value, By Product, 2017-2026 ($ Million)
Table 14    North America Plasma Fractionation Market Value, By Application, 2017-2026 ($ Million)
Table 15    North America Plasma Fractionation Market Value, By End-User, 2017-2026 ($ Million)
Table 16    North America Plasma Fractionation Market Value, By Country, 2017-2026 ($ Million)
Table 17    South America Plasma Fractionation Market Value, By Product, 2017-2026 ($ Million)
Table 18    South America Plasma Fractionation Market Value, By Application, 2017-2026 ($ Million)
Table 19    South America Plasma Fractionation Market Value, By End-User, 2017-2026 ($ Million)
Table 20    South America Plasma Fractionation Market Value, By Country, 2017-2026 ($ Million)
Table 21    Europe Plasma Fractionation Market Value, By Product, 2017-2026 ($ Million)
Table 22    Europe Plasma Fractionation Market Value, By Application, 2017-2026 ($ Million)
Table 23    Europe Plasma Fractionation Market Value, By End-User, 2017-2026 ($ Million)
Table 24    Europe Plasma Fractionation Market Value, By Country, 2017-2026 ($ Million)
Table 25    Asia-Pacific Plasma Fractionation Market Value, By Product, 2017-2026 ($ Million)
Table 26    Asia-Pacific Plasma Fractionation Market Value, By Application, 2017-2026 ($ Million)
Table 27    Asia-Pacific Plasma Fractionation Market Value, By End-User, 2017-2026 ($ Million)
Table 28    Asia-Pacific Plasma Fractionation Market Value, By Country, 2017-2026 ($ Million)
Table 29    Middle East & Africa Plasma Fractionation Market Value, By Product, 2017-2026 ($ Million)
Table 30    Middle East & Africa Plasma Fractionation Market Value, By Application, 2017-2026 ($ Million)
Table 31    Middle East & Africa Plasma Fractionation Market Value, By End-User, 2017-2026 ($ Million)
Table 32    CSL: Overview
Table 33    CSL: Product Portfolio
Table 34    CSL: Key Developments
Table 35    Grifols: Overview
Table 36    Grifols: Product Portfolio
Table 37    Grifols: Key Developments
Table 38    China Biologic Products: Overview
Table 39    China Biologic Products: Product Portfolio
Table 40    China Biologic Products: Key Developments
Table 41    Shire (Takeda Pharmaceutical Company): Overview
Table 42    Shire (Takeda Pharmaceutical Company): Product Portfolio
Table 43    Shire (Takeda Pharmaceutical Company): Key Developments
Table 44    Octapharma Plasma, Inc.: Overview
Table 45    Octapharma Plasma, Inc.: Product Portfolio
Table 46    Octapharma Plasma, Inc.: Key Developments
Table 47    Kedrion S.p.A: Overview
Table 48    Kedrion S.p.A: Product Portfolio
Table 49    Kedrion S.p.A: Key Developments
Table 50    Sanquin : Overview
Table 51    Sanquin : Product Portfolio
Table 52    Sanquin : Key Developments
Table 53    LFB SA: Overview
Table 54    LFB SA: Product Portfolio
Table 55    LFB SA: Key Developments
 

List of Figures
Figure 1    Global Plasma Fractionation Market Share, By Product, 2018 & 2026 (%)
Figure 2    Global Plasma Fractionation Market Share, By Application, 2018 & 2026 (%)
Figure 3    Global Plasma Fractionation Market Share, By End-User, 2018 & 2026 (%)
Figure 4    Global Plasma Fractionation Market Share, By Region, 2018 & 2026 (%)
Figure 5    Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 6    Global Plasma Fractionation Market Y-o-Y Growth, By Product, 2018-2026 (%)
Figure 7    Albumin: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 8    Immunoglobulins: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 9    Coagulation Factor Concentrates: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 10    Protease Inhibitors: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 11    Others: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 12    Global Plasma Fractionation Market Y-o-Y Growth, By Application, 2018-2026 (%)
Figure 13    Immunology: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 14    Neurology: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 15    Hemato-Oncology: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 16    Hematology: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 17    Critical Care: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 18    Pulmonology: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 19    Rheumatology: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 20    Others: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 21    Global Plasma Fractionation Market Y-o-Y Growth, By End-User, 2018-2026 (%)
Figure 22    Clinical Research Laboratories: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 23    Hospitals & Clinics: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 24    Academic Institutes: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 25    Others: Global Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 26    Global Plasma Fractionation Market Y-o-Y Growth, By Region, 2018-2026 (%)
Figure 27    North America Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 28    North America Plasma Fractionation Market Share, By Product, 2018 & 2026 (%)
Figure 29    North America Plasma Fractionation Market Share, By Application, 2018 & 2026 (%)
Figure 30    North America Plasma Fractionation Market Share, By End-User, 2018 & 2026 (%)
Figure 31    North America Plasma Fractionation Market Share, By Country, 2018 & 2026 (%)
Figure 32    South America Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 33    South America Plasma Fractionation Market Share, By Product, 2018 & 2026 (%)
Figure 34    South America Plasma Fractionation Market Share, By Application, 2018 & 2026 (%)
Figure 35    South America Plasma Fractionation Market Share, By End-User, 2018 & 2026 (%)
Figure 36    South America Plasma Fractionation Market Share, By Country, 2018 & 2026 (%)
Figure 37    Europe Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 38    Europe Plasma Fractionation Market Share, By Product, 2018 & 2026 (%)
Figure 39    Europe Plasma Fractionation Market Share, By Application, 2018 & 2026 (%)
Figure 40    Europe Plasma Fractionation Market Share, By End-User, 2018 & 2026 (%)
Figure 41    Europe Plasma Fractionation Market Share, By Country, 2018 & 2026 (%)
Figure 42    Asia-Pacific Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 43    Asia-Pacific Plasma Fractionation Market Share, By Product, 2018 & 2026 (%)
Figure 44    Asia-Pacific Plasma Fractionation Market Share, By Application, 2018 & 2026 (%)
Figure 45    Asia-Pacific Plasma Fractionation Market Share, By End-User, 2018 & 2026 (%)
Figure 46    Asia-Pacific Plasma Fractionation Market Share, By Country, 2018 & 2026 (%)
Figure 47    Middle East & Africa Plasma Fractionation Market Value, 2017-2026 ($ Million)
Figure 48    Middle East & Africa Plasma Fractionation Market Share, By Product, 2018 & 2026 (%)
Figure 49    Middle East & Africa Plasma Fractionation Market Share, By Application, 2018 & 2026 (%)
Figure 50    Middle East & Africa Plasma Fractionation Market Share, By End-User, 2018 & 2026 (%)
Figure 51    CSL: Financials
Figure 52    Grifols: Financials
Figure 53    China Biologic Products: Financials
Figure 54    Shire (Takeda Pharmaceutical Company): Financials
Figure 55    Octapharma Plasma, Inc.: Financials
Figure 56    Kedrion S.p.A: Financials
Figure 57    Sanquin : Financials
Figure 58    LFB SA: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report